Business
DiaSorin S p A : Strengthens its Leadership of Immuno Division with the Appointment of Gabriele Allegri as President
DiaSorin S p A : Strengthens its Leadership of Immuno Division with the Appointment of Gabriele Allegri as
About this update from Diasorin S.p.a.
Diasorin Strengthens its Leadership of Immuno Division with the Appointment of Gabriele Allegri as President Saluggia, May 4, 2026 - Diasorin (FTSE MIB: DIA) announces the appointment of Gabriele Allegri as President of the Immunodiagnostic Division. Gabriele Allegri brings to Diasorin over twenty years of international experience in leadership roles in the Pharmaceuticals, Diagnostics, and MedTech sectors, with proven ability in leading global commercial organizations in North America, EMEA, and Asia. Before joining Diasorin, he was Vice President, Global Commercial Precision Medicine at Johnson & Johnson Innovative Medicine in North America, where he led global commercial strategies for precision medicine and companion diagnostics. He served as Chair of the Precision Cancer Consortium (PCC) and was a Board member of the Precision Medicine Coalition (PMC), actively contributing to the development of the global precision medicine agenda. Throughout his career, he has played a pivotal role in the development and scaling of global precision medicine strategies, with particular focus on companion diagnostics, biomarker-driven therapies, and integrated go-to-market models covering the entire diagnostic-therapeutic continuum. "We are delighted to elcome Gabriele to Diasorin," commented Carlo Rosa, CEO of Diasorin Group. "His deep experience in precision medicine and his commitment to diagnostic ste ardship are fully aligned ith our vision for the evolution of the Immunodiagnostic Division. Gabriele ill bring distinctive capabilities in the responsible and data-driven use of diagnostics, ith the aim of improving patient outcomes and supporting the sustainability of healthcare systems, key pillars of our long-term gro th strategy." About Diasorin Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, Diasorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide. The Group operates in 5 continents through 30 companies, 4 branches, 9 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions Diasorin as the play...